Search Results - melanoma

7 Results

Sort By:

Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy

Abstract: Available for licensing from the Laboratory of Cancer Biology and Genetics of the National Cancer Institute (NCI) is a novel gene signature of thirty-seven drug-responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several...

Published: 4/8/2024 | Inventor(s): Beverly Mock, John Simmons, Aleksandra Michalowski, Jyoti Patel

Keywords(s): Histone Deacetylase (HDAC), MELANOMA, mTOR, Myeloma, Rapamycin

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy

Abstract: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery

Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Human T Cell Receptors for Treating Cancer

Abstract: T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit...

Published: 4/8/2024 | Inventor(s): Richard Morgan, Nachimuthu Chinnasamy, Steven Rosenberg

Keywords(s): COLON CANCER, Hepatocellular cancer, MELANOMA, PROSTATE CANCER, SSX

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Immunogenic Antigen Selective Cancer Immunotherapy

Abstract: Melanoma is a particularly aggressive form of cancer primarily caused by over-exposure to sunlight. Although melanoma can strike at any age, the malignancy disproportionately impacts persons of advanced age, as these individuals often have decades of repeated exposure to harmful levels of ultraviolet radiation. Scientists at NIH among others...

Published: 4/8/2024 | Inventor(s): Bira Arya, Vladimir Larionov

Keywords(s): MELANOMA, POLYPEPTIDES, SPANX-B

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Target for Anti-Tumor Immune Responses

Abstract: The Surgery Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to carry out genotypic as well as phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy. In addition, this cell line can...

Published: 4/8/2024 | Inventor(s): Steven Rosenberg, Suzanne Topalian

Keywords(s): 888-mel, CANCER, Cell line, MELANOMA

Category(s): Application > Research Materials, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma

Abstract: The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Before testing drugs in humans, drug developers are required...

Published: 5/23/2024 | Inventor(s): Chi-Ping Day, Glenn Merlino, Zoe Ohler, Rajaa El Meskini, Terry Van Dyke, Thomas Tuting

Keywords(s): Allograft, GDA, Genetically Engineered Mouse-Derived Allograft, MELANOMA, Metastasis, mouse model, Preclinical, therapeutics

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology